[go: up one dir, main page]

WO2007024744A3 - Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques - Google Patents

Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques Download PDF

Info

Publication number
WO2007024744A3
WO2007024744A3 PCT/US2006/032459 US2006032459W WO2007024744A3 WO 2007024744 A3 WO2007024744 A3 WO 2007024744A3 US 2006032459 W US2006032459 W US 2006032459W WO 2007024744 A3 WO2007024744 A3 WO 2007024744A3
Authority
WO
WIPO (PCT)
Prior art keywords
nuclear receptor
receptor ligands
carboxamide compounds
steroid nuclear
heterocyclic carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/032459
Other languages
English (en)
Other versions
WO2007024744A2 (fr
Inventor
Brenton T Flatt
Xiao Hui Gu
Richard Martin
Raju Mohan
Brett Murphy
Michael Charles Nyman
William C Stevens
Tie Lin Wang
Lynne Canne Bannen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of WO2007024744A2 publication Critical patent/WO2007024744A2/fr
Publication of WO2007024744A3 publication Critical patent/WO2007024744A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés de carboxamide hétérocycliques qui sont utiles pour moduler l'activité de récepteurs nucléaires stéroïdes. L'invention a également pour objet des compositions pharmaceutiques contenant ces composés, des procédés pour utiliser ces composés, et des procédés pour les préparer.
PCT/US2006/032459 2005-08-21 2006-08-18 Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques Ceased WO2007024744A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71027305P 2005-08-21 2005-08-21
US60/710,273 2005-08-21

Publications (2)

Publication Number Publication Date
WO2007024744A2 WO2007024744A2 (fr) 2007-03-01
WO2007024744A3 true WO2007024744A3 (fr) 2007-06-07

Family

ID=37684876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/032459 Ceased WO2007024744A2 (fr) 2005-08-21 2006-08-18 Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques

Country Status (1)

Country Link
WO (1) WO2007024744A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008288897A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
AR094411A1 (es) 2013-01-10 2015-07-29 Gruenenthal Gmbh Carboxamidas basadas en pirazolilo ii
US9206136B2 (en) 2013-01-10 2015-12-08 Grünenthal GmbH Pyrazolyl-based carboxamides I
WO2015197187A1 (fr) 2014-06-24 2015-12-30 Grünenthal GmbH Carboxamides à base de pyrazolyle v
MX2020003671A (es) 2017-10-06 2020-08-03 Forma Therapeutics Inc Inhibicion de peptidasa especifica de ubiquitina 30.
IL278291B2 (en) 2018-05-17 2023-10-01 Forma Therapeutics Inc Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
PL3860989T3 (pl) 2018-10-05 2023-07-10 Forma Therapeutics, Inc. Sprzężone piroliny, które działają jako inhibitory proteazy 30 swoistej dla ubikwityny (usp30)
EP4118081A1 (fr) 2020-03-27 2023-01-18 Landos Biopharma, Inc. Ligands de plxdc2
WO2024059524A1 (fr) * 2022-09-12 2024-03-21 Hotspot Therapeutics, Inc. Composés de pyrazolylcarboxamide et leur utilisation en thérapie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (fr) * 2001-07-20 2003-01-30 Merck & Co., Inc. Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
WO2003027076A2 (fr) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Derives de 1h-imidazole ayant une activite antagoniste de cb1
WO2003063781A2 (fr) * 2002-01-29 2003-08-07 Merck & Co., Inc. Imidazoles substitues en tant que modulateurs du recepteur cannabinoide
WO2004085419A1 (fr) * 2003-03-24 2004-10-07 Basf Aktiengesellschaft Anilide d'acide carboxylique trifluoromethylthiophene et son utilisation en tant que fongicide
WO2006076202A1 (fr) * 2005-01-10 2006-07-20 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003007887A2 (fr) * 2001-07-20 2003-01-30 Merck & Co., Inc. Imidazoles substitues servant de modulateurs de recepteurs de cannabinoides
WO2003027076A2 (fr) * 2001-09-21 2003-04-03 Solvay Pharmaceuticals B.V. Derives de 1h-imidazole ayant une activite antagoniste de cb1
WO2003063781A2 (fr) * 2002-01-29 2003-08-07 Merck & Co., Inc. Imidazoles substitues en tant que modulateurs du recepteur cannabinoide
WO2004085419A1 (fr) * 2003-03-24 2004-10-07 Basf Aktiengesellschaft Anilide d'acide carboxylique trifluoromethylthiophene et son utilisation en tant que fongicide
WO2006076202A1 (fr) * 2005-01-10 2006-07-20 Exelixis, Inc. Composes carboxamides heterocycliques utilises ent ant qu'agents pharmaceutiques

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANTOLINI M ET AL: "Analogues of 4,5-bis(3,5-dichlorophenyl)-2- trifluoromethyl-1H-imidazole as potential antibacterial agents", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 9, no. 7, 5 April 1999 (1999-04-05), pages 1023 - 1028, XP004162577 *
CAPUANO L ET AL: "Chemie der 2,3-Dihydro-2,3-diiminofurane", LIEBIGS ANNALEN DER CHEMIE, vol. 12, 1982, pages 2178 - 2188, XP002188095 *
DYCK B ET AL: "Potent imidazole and triazole CB1 receptor antagonists related to SR141716", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 5, 8 March 2004 (2004-03-08), pages 1151 - 1154, XP001197288 *
GOMPPER R ET AL: "Umsetzung von Imidazolen mit Isocyanaten", CHEMISCHE BERICHTE, vol. 92, no. 3, 12 March 1959 (1959-03-12), pages 550 - 563, XP002378856 *
KUDO N ET AL: "Synthesis and herbicidal activity of 1,5-diarylpyrazole derivatives", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 47, no. 6, 1999, pages 857 - 868, XP001026111 *
LAN R ET AL: "Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 4, 1999, pages 769 - 776, XP002145465 *
PAPADOPOULOS E P: "Reactions of imidazoles with isocyanates at elevated temperature", JOURNAL OF ORGANIC CHEMISTRY, vol. 42, no. 24, 25 November 1977 (1977-11-25), pages 3925 - 3929, XP002378857 *
SHIM J-Y ET AL: "Molecular interaction of the antagonist N-(piperidin-1-yl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 7, March 2002 (2002-03-01), pages 1447 - 1459, XP002968557 *
TRANBERG C E ET AL: "2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A1 adenosine receptors", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 45, no. 2, 19 December 2002 (2002-12-19), pages 382 - 389, XP002378855, ISSN: 0022-2623 *
UEDA T ET AL: "A novel ring transformation of 5-acylaminouracils and 5-acylamino-pyrimidin-4(3H)-ones into imidazoles", TETRAHEDRON LETTERS, vol. 29, no. 36, 1988, pages 4607 - 4610, XP001038533 *

Also Published As

Publication number Publication date
WO2007024744A2 (fr) 2007-03-01

Similar Documents

Publication Publication Date Title
TW200607798A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2007111864A3 (fr) Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
WO2008070462A3 (fr) N-oxydes d'analogues 4,5-époxy-morphinanium
WO2006104826A3 (fr) Composes antagonistes du recepteur du glucagon, compositions renfermant de tels composes et methodes d'utilisation
IL185353A0 (en) Azabicycloalkane derivatives , pharmaceutical compositions containing the same and methods for the preparation thereof
TW200605882A (en) Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
WO2006034039A3 (fr) Morphinanes substitues et leurs procedes d'utilisation
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
IL187713A0 (en) 3-aminocarbazole compounds, pharmaceutical composition containing the same and method for the preparation thereof
WO2005033073A3 (fr) Derives heterocycliques spirocycliques et leurs methodes d'utilisation
IL214183A (en) Pharma-informatics system and method, preparation for use with it and method for preparation of the preparation
IL180508A0 (en) Modified pyrimidine glucocorticoid receptor modulators
WO2007038669A3 (fr) Composes et compositions contenant de la diarylamine, et utilisation en tant que modulateurs de recepteurs de c-kit
WO2010039977A3 (fr) Antagonistes d'hétéroaryle des récepteurs de la prostaglandine d2
EP1814885A4 (fr) Nouveaux composes bicycliques heterocycliques, leur procede de preparation et compositions les contenant
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2007050802A3 (fr) Nouveaux antagonistes opioides
SI1720544T1 (sl) Novi azabicikliäśni derivati, postopek za njihovopripravo in farmacevtski sestavki, ki jih vsebujejo
HUP0401522A2 (en) New 4-benzylidene-piperidine derivatives, pharmaceutical compositions containing the same and process for their preparation
WO2006119510A3 (fr) Isoformes d'un recepteur pour produits de glycation avancee (rage) et methodes d'identification et d'utilisation de celles-ci
WO2007024744A3 (fr) Composes de carboxamide heterocycliques en tant qu'agents pharmaceutiques
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
WO2006105442A3 (fr) Derives spirocycliques heterocycliques et procedes d'utilisation
WO2006138347A3 (fr) Composes modulateurs du recepteur des androgenes et procedes associes

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06801924

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06801924

Country of ref document: EP

Kind code of ref document: A2